We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Uc25.0
UC-II Research
Mostly mechanism / observational
15 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most UC-II studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2009–2026 with a typical study size of 106 participants.
Based on 15 studies · 1 meta-analysis · 9 RCTs · 2,933 total participants
Confidence
High confidence
By outcome
Joint pain & arthritisModest reduction in knee osteoarthritis pain/stiffness and improved joint flexibility · 8-24 weeks
Mostly mechanism / observational12 studies
InflammationInferred from the oral-tolerance mechanism (no inflammatory-biomarker outcomes measured) · 8-24 weeks
Mostly mechanism / observational12 studies
Active research area
11 studies in the last 5 years · Latest meta-analysis: 2025
200920172026
1RCT2023
Shiojima Y, Takahashi M, Takahashi R, Maruyama K, Moriyama H, Bagchi D · J Am Nutr Assoc (2023)
In plain English: Future research should include larger trials, biomarker studies, MRI imaging, and real-world data to confirm disease-modifying potential.
Prabhoo R, Patel S, Sardar I, Jangid S, Thirupathy RV, Roy R. · Cureus (2026)
An evidence-based analysis showed that undenatured type II collagen (40 mg/day) improves pain, stiffness, function, and quality of life in early-to-moderate OA (Grades 1-3), with benefits observed within eight weeks, improved compliance, and non-steroidal anti-inflammatory drug-sparing effects.
Comparative evidence favors UC-II® (Lonza Greenwood LLC, USA) over other sources, highlighting the importance of product selection.
Expert consensus recommends undenatured type II collagen as a nutraceutical adjunct with physiotherapy for long-term use in responders.
In plain English: Chondroprotectors containing CS and GS combined with UC-II are actively used in clinical practice in patients with OA and LBP as part of medicine products and pharmaconutraceuticals.
Shavlovskaya OA. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2024)
UC-II inhibits cartilage destruction at any stage of the disease through the mechanism of immune tolerance, which «trains» the immune system to be tolerant to the antigens of the destroyed cartilage.
There is ample evidence of the successful use of pharmaconutraceuticals based on CS, GS, and UC-II molecules (Chondroguard TRIO) in patients with chronic LBP due to facet joint OA.
Recent studies assessed the effect of vitamins D 3 and K 2 and their combination on OA pathogenesis.
In plain English: J Integr Med. 2025; 23(4): 357-369.
Chen CS, Wen L, Yang F, Deng YC, Ji JH, Chen RJ, Chen Z, Chen G, Gu JY. · Journal of integrative medicine (2025)
In the WOMAC pain score, the SUCRA of passion fruit peel extract was 91% (mean difference [MD]: -9.2; 95% confidence interval [CI]: [-16.0, -2.3]), followed by methylsulfonylmethane (89%), undenatured type II collagen (87%), collagen (84%), and Lanconone (82%).
The SUCRA (99%) of passion fruit peel extract (MD: -41.0; 95% CI: [-66.0, -16.0]) ranked first in terms of the WOMAC function score, followed by Lanconone (95%), collagen (86%), ParActin (84%), and Lactobacillus casei strain Shirota (83%).
The top three total rankings are passion fruit peel extract (95.0%), Lanconone (88.5%), and collagen (85.0%).
In plain English: An RCT in healthy subjects with exercise-related joint discomfort found UC-II 40mg improved knee extension and extended pain-free exercise time.
Lugo JP et al. · J Int Soc Sports Nutr (2013)
Improved average knee extension range vs placebo
Extended time to joint discomfort during strenuous exercise
In plain English: Conclusion The results of the study confirm the good effectiveness and safety of the Artneo combination in patients with OA of the knee joints.
Materials and methods The study included 212 patients from 12 centers in the Russian Federation, of whom 50 had radiological stage III knee OA: 41 (82.0%) females and 9 (18.0%) males aged 44 to 75.
The effectiveness of therapy was assessed by the change of pain using the Visual Analog Scale, the WOMAC index, KOOS, the EQ-5D quality of life questionnaire, and the need for non-steroidal anti-inflammatory drugs.
All patients had a complete blood count, urinalysis, blood chemistry, and ultrasonic examination of the target knee joint.
In plain English: A 90-day controlled study (n=105, ages 60-80) found adding UC-II to standard osteoarthritis care improved physical quality of life, pain, and function.
Sadigursky D et al. · Acta Ortop Bras (2022)
Improved physical-domain quality of life, pain, and function vs control